- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02141139
Perioperative Inflammation and Breast Cancer Outcome
May 14, 2014 updated by: Seok Jin Nam, Samsung Medical Center
Suppression of Inflammation by Using NSAIDs During Peri-operative Period Can Affect the Prognosis of Breast Cancer.
It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent the several cancers.
In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory drug) has been suggested.However, there was no consistent results.
surgery is main cause of inflammation for cancer patients.
Therefore, we want to know the association between prevention of perioperative inflammation with NSAIDS and breast cancer outcomes.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
1568
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Breast cancer patients who took the surgery
Exclusion Criteria:
- underlying medical disease (major heart disease, lung disease, coagulopathy)
- major psychologic disease (major depression, schizophrenia, manic disorder)
- pregnancy
- rheumatic disease patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control arm
no medication or acetaminophen
|
|
|
Experimental: NSAIDS (ketorolac intravenous, ibuprofen)
ketorolac IV (just before surgery) and ibuprofen for 1 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
disease free survival
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
overall survival
Time Frame: 5years
|
5years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
neutrophil-lymphocyte ratio (NLR), albumin, inflammatory blood lab (CRP)
Time Frame: POD 1-2 weeks (immediate postoperative period)
|
POD 1-2 weeks (immediate postoperative period)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Anticipated)
January 1, 2016
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
October 21, 2013
First Submitted That Met QC Criteria
May 14, 2014
First Posted (Estimate)
May 19, 2014
Study Record Updates
Last Update Posted (Estimate)
May 19, 2014
Last Update Submitted That Met QC Criteria
May 14, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Inflammation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ketorolac
- Ibuprofen
Other Study ID Numbers
- 2009-11-036
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Cancer | Breast Carcinoma | Malignant Neoplasm of Breast | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Massachusetts General HospitalMassachusetts Institute of TechnologyNot yet recruitingBreast Cancer | Breast Asymmetry | Breast Abnormalities | Breast LesionUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastUnited States
Clinical Trials on NSAIDS (ketorolac and ibuprofen)
-
The University of Texas Health Science Center,...Withdrawn
-
Cairo UniversityNot yet recruitingPostoperative Pain | Bariatric Surgery CandidateEgypt
-
Benazir Bhutto Hospital, RawalpindiCombined Military Hospital, PakistanCompletedPostoperative Pain | Intravenous Drug Usage | Knee Arthroscopy | Ibuprofen | KetorolacPakistan
-
Cairo UniversityCompletedColorectal Cancer | Ibuprofen | KetorolacEgypt
-
Cumberland PharmaceuticalsCompleted
-
Cumberland PharmaceuticalsCompletedArthroscopic Knee SurgeryUnited States
-
Madigan Army Medical CenterTerminatedInfertility, FemaleUnited States
-
Cairo UniversityCompletedPostoperative Pain | HysterectomyEgypt
-
Sheba Medical CenterCompleted
-
Culpeper Surgery CenterCumberland PharmaceuticalsUnknownChronic Pelvic PainUnited States